ASA Community

Past Award Winners

RIW: Best Poster  Student Travel
JSM:  Best Paper Best Poster Best Student Paper
NCB:  Best Paper

Scholarship Award

2022

Larry Han, Harvard University
Sasha Kravets, University of Illinois at Chicago
Lianlian Du, University of Wisconsin
Chenqi Fu, Pennsyvlania State University

2021

Siddhesh Kulkarni, University of Louisville
Ruizhe Chen, University of Illinois at Chicago
Michael Lucagbo, University of Maryland
Inkoo Lee, Florida State University
Mian Arif Shams Adnan, Bowling Green State University

2020

Bryan Blette (UNC, Chapel Hill)
Yan Gao (Univ Illinois, Chicago)
Yunasa Olufadi (Univ Memphis)
Liwen Wu (Univ Pittsburgh)
Xiao Wu (Harvard)

2019

Busola Ololade Sanusi, UNC-Chapel Hill
Laura Elizabeth (Beth) Wiener, UNC-Chapel Hill
Nina Zhou, University of Michigan Ann Arbor

2018

Christopher R. Barbour, Montana State University
Thevaa Chandereng, University of Wisconsin at Madison
Will A. Eagan, Purdue University

Best Poster Award at Regulatory-Industry Statistics Workshop
2019

First: Yong Lin, Zhen Zhang, Jingyi Liu, Eli Lilly and Company, Probability of Study Success (PrSS) Evaluation Based on Multiple Endpoints in Immuno-Oncology (IO)
Second: Guanglei Yu, Yuanyuan Bian, Margaret Gamalo-Siebers, Eli Lilly and Company, Entropy Balance Weighting and Power Priors: Its use in Real World Data (RWD) and Disproportionate Randomized-Controlled Trials (RCTs)
Third: Nadeesri Wijekoon, Oluwatobi Aduroja, Jessica M. Biggs, Megan Ehret, Vijay Ivaturi, Dina El-Metwally, Mathangi Gopalakrishnan,University of Maryland, Baltimore County, Model-Based Approach to Optimize Clinical Outcomes in Neonatal Opioid Withdrawal Syndrome using Real World Data

2018

First: Koko Asakura, National Cerebral and Cardiovascular Center, Toshimitsu Hamasaki, National Cerebral and Cardiovascular Center, & Scott R. Evans, Harvard School of Public Health, Interim monitoring for futility in clinical trials with co-primary endpoints
Second: Caimiao Wei, Satrajit Roychoudhury, Pfizer Inc, Co-development of Multiple Drug Combinations in Oncology: A Bayesian Design for Dose Finding
Third: Dongyuan Xing, Jane Wu, Matthew Guo, Eisai Inc. Considerations on Group Sequential Design for Multiple Endpoints with Different Information Fractions

2017

First: Ji Lin, Zachary M. Thomas, Jingyi Liu & Mythili Koneru, Eli Lilly & Company, A Bayesian Hierarchical Model for Indirect Comparison of Immuno-oncology Drugs
Second: Zhen Zeng, Meihua Wang, Xinxin Shu & Cong Chen, Merck Research Laboratories, Improving Dose-finding Methods for Early Oncology Combination Trials
Third: Wijith Munasinghe, Xin Qi & BoTong, Abbvie, Inc, Safe and Faster Way to Reach Maximum Tolerated Dose (MTD) in Phase I Oncology Trials

2016

First: Toshimitsu Hamasaki, National Cerebral and Cardiovascular Center, Tomoyuki Sugimoto, Kagoshima University, Koko Asakura, National Cerebral and Cardiovascular Center & Scott R. Evans, Harvard School of Public Health, Early Evaluation of Efficacy in Group-Sequential Clinical Trials with Two Time-to-Event Outcomes

Student Travel Award for Regulatory-Industry Statistics Workshop
2020

Zhaohu (Jonathan) Fan, University of Cincinnati Lidner College of Business
Rupam Bhattacharyya, University of Michigan
Michael Daniel Cid Lucagbo, University of Maryland, Baltimore County
Thevaa Chandereng, University of Wisconsin
Jinyi Zhou, Duke University
Ariel Chernofsky, Boston University School of Public Health

2019

Peifeng Ruan, The George Washington University
Steve B. Ampah, University of Alabama at Birmingham
Song Zhai, University of California, Riverside
Meizi Liu, University of Chicago
Juhyun Kim, University of California, Los Angeles
Jinyuan Liu, University of California, San Diego
Xiao Wu, Harvard University
Weiji Su, University of Cincinnati
Ryan Thomas Jarrett, University of Cincinnati
Yizhe Xu, University of Utah

2018

Yu Cao, Virginia Commonwealth University
Xiaowu Dai, University of Wisconsin – Madison
Lin Dong, North Carolina State University
Jing Li, Indiana University
Brooke Ann Rabe, University of Arizona
Di Zhang, University of Pittsburgh
Heng Zhou, MD Anderson Cancer Center
Yanhong Zhou, MD Anderson Cancer Center

Best Contributed Paper Award at Joint Statistical Meetings
2019

First: Devan Mehrotra, Merck & Co, Survival Analysis Using a 5-STAR Approach in Randomized Clinical Trials
Second: Susan S. Ellenberg, University of Pennsylvania, Emerging Changes in DMC Oversight
Third: Wenting Cheng, Biogen, Analysis of Multiple Outcome Measures with Applications to Disability Improvement in Multiple Sclerosis
Honorable Mention: Paul Gallo, Novartis Pharmaceuticals, Implementing Effective DMC Decision-Making in Complex Clinical Trial Designs
Honorable Mention: Veronica Bunn, Takeda Pharmaceuticals, Flexible Semiparametric Bayesian Hierarchical Model for Basket Trials
Honorable Mention: Mary Ryan, University of California, Irvine, An Extension of Cohen’s Kappa for Clustered Data and Group Sequential Testing

2018

First: James Buchanan, Covilance, LLC, Specific Safety Monitoring Tools and How This Will Benefit Drug Safety
Second: Barbara Hendrickson, AbbVie, Going from the Program Safety Analysis Plan to the Aggregate Safety Analysis Plan
Third: Lee Kennedy-Shaffer, Harvard University Department of Biostatistics, Sample Size Estimation for Stratified Cluster Randomized Trials with Binary Outcomes
Honorable Mention: Lothar Tremmel, CSL Behring, Quantitative Regulatory Landscape
Honorable Mention: Weidong Zhang, Pfizer, Leveraging Omics Biomarker in Early Clinical Trials - Concept, Utility and Impact on Decision Making

2017

First: Devan Mehrotra, Qian Guan and Zifang Guo, Merck Research Laboratories, A Powerful Learn-And-Confirm Pharmacogenomics Methodology for Randomized Clinical Trials
Second: Alexia Lasonos, Memorial Sloan Kettering Cancer Center, Measure Differential Treatment Benefit Across Marker Specific Subgroups: The Choice of Outcome Scale
Third: Brian Wiens and Llya Lipkovich, Aquinox Pharmaceuticals, Inc, Implementing Multiple Imputation in Non-inferiority Clinical Trials
Honorable Mention: Steven A. Julious and Jo Rothwell, The University of Sheffield, A Review of the Sample Size Calculations of Randomised Controlled Trials Funded by One of the Leading Funders in the UK.
Honorable Mention: William R. Sones and Jonathan Cook, University of Oxford, Achieving Consensus on Guidance for Specifying the Target Difference in a RCT Sample Size Calculation – DELTA2 Project

2016

First: Scott Berry, Berry Consultants, Using Little 'Go' Decisions
Second: Susan Urach, Medical University of Vienna, Multi-Arm Group Sequential Designs with Simultaneous Stopping Rule
Second: Gerald Hlavin, Medical University of Vienna, An extrapolation Framework to Specify Requirements for Drug Development in Children
Third: Tobias Mielke, ICON PLC, Interim Timing in Adaptive Two-Stage Dose-Finding Studies: What happens to the Expected Benefit?
Honorable Mention: Brian Wiens, Allergan, The Role of Multiple Imputation in Noninferiority Trials.
Honorable Mention: Ming Zhou, Bristol-Myers Squibb, Interim Go/No=Go Decision Making in Clinical Trials with Longitudinal Outcomes

2015

First: Devan V. Mehrotra, Merck, How to Strengthen Analyses by Dropping Risky Assumptions: Three Examples
Second: Steven Snapinn, Amgen, Is the Median PFS Difference Meaningful for Assessing Treatment Effect?
Third: Kristine Broglio, Berry Consultants, A Prospective Bayesian Adaptive Trial with Hierarchical Borrowing from a Prior Single Arm Study
Third: Noah Simon, University of Washington Department of Biostatistics, Selection Bias in Adaptive Enrichment Designs
Honorable Mention: Zifang Guo, Merck, Missing Data Analysis in Crossover Studies with Baseline Measurements and Small Sample Sizes
Honorable Mention: Kunthel By, FDA, Ruling Out a Safety Margin

2014

First: Devan V. Mehrotra, Merck & Co, More Powerful Analyzes of Crossover Trials with Baseline Measurements
Second: Scott R. Evans, Harvard School of Public Health, Using Endpoint Data to Analyze Patients Rather Than Patient Data to Analyze the Endpoints
Third: Sharon Murray, Parexel Ltd & Allison M. Florance, Novartis Oncology, Transitioning from 3+3 to N-CRM at GlaxoSmithKline
Honorable Mention: Richard Forshee, FDA-Center for Biologics Evaluation and Research, Communicating Benefit-Risk Analysis Results Using Graphics
Honorable Mention: Michael Hale, Baxalta US Inc, When is Data Transparency Useful?
Honorable Mention: Jesse Berlin, Johnson & Johnson, Sharing Clinical Trial Data: Recent Experience and Issues Raised

2013

First: Corine Baayen, H. Lundbeck A/S & Philip Hougaard, Lundbeck, Testing Effect of a Drug Using Multiple Models for the Dose-Response
Second: Yonghong Gao, US Dept of Health and Human Services, Adaptive Enrichment Design in Clinical Trial
Third: Min Lin, Sample Size Re-Estimation in Confirmatory Studies, FDA/CBER
Honorable Mention: Heng Li, FDA/CDRH & Vandana Mukhi, FDA/CDRH, Design Considerations in Testing Superiority and Noninferiority Hypotheses for a Set of Secondary Endpoints
Honorable Mention: Nelson Lu, FDA/CDRH & Yunling Xu, FDA/CDRH, Statistical Considerations and Approaches on Using OUS Data to Support a Pre-Market Application of Medical Devices

2012

First: Scott Emerson, University of Washington, Active Control Trials with Adaptive Modification of Margin to Address Nonconstancy
Second: Jason Connor, Berry Consultants, A Case Study of a Bayesian Adaptive Cardiology Device Trial Leading to Approval
Third: Steven Julious, University of Sheffield, The ABC Assumptions of Setting a Noninferiority Margin: When the Margin Assumptions Can Be Violated
Honorable Mention: Ilya Lipkovich, Quintiles, Strategies for Identifying Predictive Biomarkers in Clinical Trials Using Variable Importance
Honorable Mention: Carl Dicasoli, Vertex Pharmaceuticals, Interim Analysis of Constancy for Noninferiority Testing in Active Controlled Clinical Trials

2011

First: Christopher Tong, U.S. Department of Agriculture, Concordance Correlation Coefficient Decomposed into the Product of Precision and Accuracy
Second: Gang Chen, Johnson & Johnson Pharmaceutical R&D, Design and Operational Issues in Clinical Trials with Adaptive Design
Third: Radha Railkar, Merck & Co, An Overview of Different Methods to Assess Agreement in Early Phase Clinical Trials
Honorable Mention: Paul Schuette, U.S. Food and Drug Administration/CDER, Confidence Intervals for Binomial Proportions with Applications to Product Safety Signaling in Drug Exposure Registries

2010

First: Demidenko E
Second: Stroup W
Third: Murray SC
Honorable Mention: Berry D
Honorable Mention: Jones B

2009

First: Gould A
Second: Chuang-Stein C
Third: Musser B
Honorable Mention: Hendrix S

2008

First: Mukhi V
Second: Hedeker D
Third: Zhou Y
Honorable Mention: Bretz F
Honorable Mention: Sun X

2007

First: Mehrotra D
Second: Hendrix S
Third: Mehta C
Honorable Mention: Greco W
Honorable Mention: Naftel D

2006

First: Not Reported
Second: Nguyen H
Third: Remlinger K

2005

First: Mehrotra D
Second: Dmitrienko A
Third: Mallinckrodt C

2004

First (tied): Mehrotra D & Gennings C
Third: Devanarayan V

2003

First: Nguyen H
Second: Yang P
Third: Baughman A

2002

First: Senn S
Second: Mehrotra D
Third: Eberly L

2001

First: Baggerly K
Second: Wiens B
Third: Holmgren E

2000

First: Goldsmith C
Second: Devanarayan V
Third: Wiens B

1999

First: Railkar R
Second: Bohidar N
Third: Helms L

1998

First: Tangen C
Second: Mehrotra D
Third: Meier K

Best Contributed Poster Award at Joint Statistical Meetings
2020

First: “Impact of Direction of Treatment Effect on Composite Time-to-event Endpoint Via Win Ratio Analysis” by Ran Liao, Sujatro Chakladar, Margaret Gamalo (Eli Lilly)
Second: “Reginal Efficacy Evaluation in Multi-Reginal Clinical Trials Using a Discounting Factor Weighted Z Test” by XuanxuanYu, JianlingBai, Hao Yu, JingweiWu (Nanjing Medical Univ, Univ of South Carolina, Temple Univ)
Third: “Interim Monitoring in Sequential Multiple Assignment Randomized Trials” by Liwen Wu, Junyao Wang, and Abdus S. Wahed (Univ. of Pittsburg)

2019

First: Yun Bai (Medtronic PLC), Zengri Wang, Ted Lystig, and Baolin Wu, Statistical methods for equivalency test in oxymetry comparison study
Second: Holly Hartman (University of Michigan), Matthew Schipper, and Kelley Kidwell, Small Sample Sequential Multiple Assignment Randomized Trials with Continuous Outcomes
Third: Jessie Gu (Novartis), Estimand and analysis consideration in a Phase III study of CAR-T (BELINDA) with delayed treatment effect
Honorable Mention: Phebe Kemmer (Eli Lilly), Tianle Hu, Fanni Natanegara, Zachary Thomas, and Himanshu Upadhyaya, A comparison of migraine prevention therapies in the adult versus pediatric populations using a joint Bayesian network meta-analysis model
Honorable Mention: Helen Chen (GlaxoSmithKline), Jonathan Haddad, and Xiaowei Wang, Less is More – Adaptive Seamless Phase II/III Design

2018

First: Tian Chen, Ye Feng, Shu-Pang Huang, Ming Zhou & Ramachandran Suresh, Bristol Myers-Squibb, Determination of Optimal Cut-off Points for Biomarkers in Oncology Research
Second: Ellen B. Gurary & Joseph Massaro, Boston University Non-Inferiority Margins in Superiority/Non-inferiority Seamless Clinical Trials
Third: Ronnie Wang, Daoyuan Shi, Huaming Tan, Neal Thomas, Dan Meyer, Pfizer and the University of Connecticut (Shi), Power and Type I Error for Sizing Binomial Endpoints with Unequal Randomization Ratios

2017

First: Tian Chen, Ye Feng, Shu-Pang Huang, Ming Zhou & Ramachandran Suresh, Bristol Myers-Squibb, Determination of optimal cut-off points for biomarkers in oncology research
Second: Ellen B. Gurary & Joseph Massaro, Boston University Non-Inferiority Margins in Superiority/Non-inferiority Seamless Clinical Trials
Third: Ronnie Wang, Daoyuan Shi, Huaming Tan, Neal Thomas, Dan Meyer, Pfizer and the University of Connecticut (Shi) Power and Type I Error for Sizing Binomial Endpoints with Unequal Randomization Ratios

2016

First: Mingyue Wang & Pinyuen Chen, Syracuse University, A Curtailed Design for Selecting the Best Among Bernoulli Treatment and Control
Second: Kijoeng Nam, Merck; Nicholas Henderson, Johns Hopkins University; Dai Feng, Merck Survival Prediction in Early-stage Lung Cancer via Bayesian Model Averaging of Nonparamateric Accelerate Failure Time Models
Third: Jimmy Wong, FDA/CDER, An R Shiny Foundation for Standardization Clinical Review Tools

2015

First: Zhongying Xu,John A. Kellum, Gary M. Marsh & Chung-Chou H. Chang, University of Pittsburgh, Optimal Sample Size Determination for Adaptive Seamless Phase II/III Design
Second: Ginto J Pottackal & Thomas Mathew, University of Maryland at Baltimore County, Tolerance Intervals for the Assessment of Biosimilarity
Third: Yueqin Zhao, Rima Izem & Mark Levenson, FDA/CDER, Is Type I Error Control for Multiplicity Really "Out of the Picture" in Pharmacoepidemiology?

2014

First: Xie Diqiong, FDA, A Simulation Study Using Inverse Probability Weighting to Adjust for Multiple Types of Bias in Observational Studies
Second: Shuyen Ho, PAREXEL International, Data-Driven Prior Distributions for a Phase 2 COPD Dose-Finding Clinical Trial
Third: Yi Deng, Department of Biostatistics and Bioinformatics, Emory University, Modeling and Prediction of Accrual in Multi-Regional Clinical Trials

2013

First: Bo Huang & Neal Thomas, Pfizer Inc, Optimal Designs with Interim Analyses for Randomized Studies with Long-term Time-specific Endpoints
Second: Richard J. Willke, Ching-Ray Yu, Birol Emir, Kelly H. Zou, Pfizer Inc. & Javier Cabrera, Rutgers University, A Comparison and Integration of Quantile Regression and Finite Mixture Modeling
Third Place: Kijoeng Nam & Estelle Russek-Cohen, FDA/CBER, Logistic Regression Likelihood Ratio Test Analysis and Harnessing Graphics to Explore Safety Data in the Vaccine Adverse Event Report System (VAERS)

2012

First: Li Wang & Weihua Tang, Bristol-Myers Squibb, Meta Analysis for All-cause Death for Apixaban vs. Placebo Or Control in SPAF Trials
Second: Jianing Di, Xin Zhao, Daniel Wang, Ming Lu, & Michael Krams, Janssen Research & Development, Assessing the Cumulative Exposure Response in Alzheimer Disease Studies
Third: Kelly H. Zou, Ching-Ray Yu, Ye Tan & Martin O. Carlsson, Pfizer Inc, Comparative Effectiveness Research Using Meta-Analysis to Evaluate and Summarize Diagnostic Accuracy

2011

First: Junxiang Luo & Yongming Qu, Eli Lilly & Company, Comparison of Negative Binomial Regression Models in Analyzing Hypoglycemia Events
Second: David Kerr & Shannon Grant, Axio Research, Creating a Better, Shorter DMC Report: A Stack of Needles, Not a Needle in a Haystack
Third: Alexandra I. Barsdorf, Kelly H. Zou, Martin O. Carlsson, & Joseph C. Cappelleri, Pfizer Inc., Methods for Responder Analysis of Patient-Reported Outcomes

2010

First: Carlsson M
Second: Zou K
Third: Zhao Y

2009

First: Dragomir A
Second: Zou K
Third: Gaffney M

2008

First: Zou K
Second: Siqueira A
Third: Coar W

Student Paper Award at Joint Statistical Meetings
2020

First: Xinzhou Guo, University of Michigan, Inference on Selected Subgroups in Clinical Trials
Second: Duzhe Wang, University of Wisconsin-Madison, Boosting Algorithms for Estimating Optimal Treatment Rules
Third: Dana Johnson, North Carolina State University, One-Step Value Difference Test for The Existence of a Subgroup with Beneficial Treatment Effect Using Random Forests
Honorable Mention: Thevaa Chandereng, University of Wisconsin-Madison, Robust Blocked Response-Adaptive Randomization Designs

2019

First: Ting Ye, University of Wisconsin-Madison, Validity and robustness of tests in survival analysis under covariate-adaptive randomization

2018

First: Jiaying Lyu, University of Chicago, AAA: Triple-adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose-finding trials
Second: David Cheng, Department of Biostatistics, Harvard University, The Statistical Performance of Matching-Adjusted Indirect Comparisons
Third: Arjun Sondhi, Department of Biostatistics, University of Washington, The Reduced PC-Algorithm: Improved Causal Structure Learning in Large Random Networks
Honorable Mention: Ting Ye, Department of Statistics, University of Wisconsin-Madison, A Robust Approach to Sample Size Calculation in Cancer Immunotherapy Trials with Delayed Treatment Effect
Honorable Mention: Kan Li, University of Texas Health Science Center at Houston, Bayesian Personalized Multi-Criteria Benefit-Risk Assessment of Medical Products

2017

First: Nathaniel O’Connell, Medical University of South Carolina, A latent variable approach to elicit continuous toxicity scores and severity weights for multiple toxicities in dose-finding oncology trials
Second: Zhengling Qi, University of North Carolina at Chapel Hill, D-learning to estimate optimal individual treatment rules
Third: Menghan Li, Pennsylvania State University, Joint analysis of left-censored longitudinal biomarker and binary outcome via latent class modeling
Honorable Mention: Florica Constantine, Johns Hopkins University, A Bayesian adaptive subgroup identification enrichment design
Honorable Mention: Lie Li, Southern Methodist University, Meta-analysis of rare binary events in treatment groups with unequal variability

2016

First: Jingxiang Chen, University of North Carolina – Chapel Hill, Estimating Individualized Treatment Rules for Ordinal Treatments
Second: Ailin Fan, North Carolina State University, Change-Plane Analysis for Subgroup Detection and Sample Size Calculation
Third: Yiyi Chu, University of Texas , Adaptive Dose Modification for Phase I Clinical Trials
Honorable Mention: Xin Lu, Emory University, Evaluating the Effect of Delayed PEG Insertion in Patients Diagnosed with ALS via Adaptive Treatment Length Regimens
Honorable Mention: Geoffrey Johnson, University of Pittsburgh, Optimizing Dynamic Treatment Regimes via Threshold Utility Analysis on Quality Adjusted Lifetime for Subgroup Analysis in Clinical Trials
Honorable Mention: Susanne Urach, Medical University of Vienna, Multi-arm Group Sequential Designs with Simultaneous Stopping Rule
Honorable Mention: Soyeon Kim, Rice University, Prediction-Oriented Marker Selection (PROMISE) with application to high-dimensional regression

2015

First: Ying Liu, Columbia University, Sequential Multiple Assignment Randomization Trials
Second: Yebin Tao, University of Michigan, Optimal Dynamic Treatment Regimes for Treatment Initiation
Third: Patrick Schnell, University of Minnesota, A Bayesian Hierarchical Modeling Approach to Identifying Subgroups
Honorable Mention: Priyam Mitra, Rutgers University, Dose Finding Strategies In Combination Therapy
Honorable Mention: Lu Mao, University of North Carolina, Semiparametric Proportional Rates Regression

2014

First: Yanxun Xu, University of Texas at Austin, Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials
Second: Qing Liu, University of Pittsburgh, Landmark Proportional Subdistribution Hazards Models for Dynamic Prediction of Cumulative Incidence Probabilities
Third: Lee McDaniel, University of Wisconsin-Madison, Sample Size Under the Additive Hazards Model
Honorable Mention: Guang Yang, Rutgers University, Meta-analysis of rare events: From combining confidence intervals to combining confidence distributions
Honorable Mention: Pallavi S. Mishra-Kalyani, Emory University, Propensity Process for Time-varying Covariates with Application to Assessing Treatment Effect in ALS Patients

2013

First: Jing Zhou, University of North Carolina, Information-Based Sample Size Re-estimation in Group Sequential Design for Longitudinal Trials
Second: Chen Hu, University of Michigan, A Frailty-based Progressive Multistate Model for Progression and Death in Cancer Studies

2012

First: Kelley Kidwell, University of Pittsburgh, Weighted Log-rank Statistic to Compare Shared-Path Adaptive Treatment Strategies
Second: Jonathan Yabes, University of Pittsburgh, Semiparametric Estimation in the Proportional Subdistribution Hazards Model with Missing Cause of Failure
Third: Chunyan Cai, Texas MD Anderson Cancer Center, Bayesian Adaptive Phase II Screening Design for Combination Trials
Honorable Mention: Layla Parast, Harvard University, Landmark Estimation of Survival Incorporating Intermediate Event Information in a Randomized Clinical Trial

2011

First: Vock D

2010

First: Zhao S
Second: Cho Y

2009

First: Hennessey V

2008

First: Wang R

2007

First: Feng W

2006

First: Dai H
Honorable Mention: Spann M
Honorable Mention: Lewin D

2005

First: Sun J

2004

First: Chen J & McHenry M
Honorable Mention: Feng S
Honorable Mention: Wang X
Honorable Mention: Serban N

2003

First: Wahed A, Peng X, He W, Remlinger K & Serban N

2002

First: Johnson B & McNally R

2001

First: Huang X, Hyslop T, Li L & Song X

2000

First: Bryan J, Yu D, Somayaji V, Yu Q & Shang Z

1999

First: Railkar R, Burzykowski T, Tang S & Allen A

The "Stan Altan" Best Nonclinical Biostatistics Paper Award

2021

1st Place: Burdick, R. K., Thomas, N., & Cheng, A. (2017). Statistical considerations in demonstrating CMC analytical similarity for a biosimilar product. Statistics in Biopharmaceutical Research, 9(3), 249-257.
2nd Place: Novick, S. J., Christian, E., Farmer, E., & Tejada, M. (2021). A Bayesian statistical approach to continuous qualification of a bioassay. PDA Journal of Pharmaceutical Science and Technology, 75(1), 8-23.
3rd Place: Sondag, P., & Lebrun, P. (2020). Risk-based similarity testing for potency assays using MCMC simulations. Statistics in Biopharmaceutical Research, 1-10.

2019

Zeng, L., Novick, S., Yu, B., and Yang, H. (2019). “General Framework for Equivalence Testing over a Range of Linear Outcomes with CMC Applications”, Statistics in Biopharmaceutical Research, 11(2), 182-190.

2017

Zhang, J., Li, W., Roskos, L, and Yang H. (2017). “Immunogenicity assay cut point determination using nonparameteric tolerance limit”, Journal of Immunological Methods, 442, 29-34.

2015

Novick, S., Shen, Y., Yang, H., Peterson, J., LeBlond, D., and Altan, S. (2015). “Dissolution Curve Comparisons through the F2 Parameter, a Bayesian Extension of the f2 Statistic”, Journal of Biopharmaceutical Statistics, 25(2), 351-371.Bottom of Form

Chen, G., Zhong, H., Belousov, A., and Devanarayan, V. (2015). “A PRIM Approach to Predictive-signature Development for Patient Stratification”, Statistics in Medicine, 34, 317–342.

Return to Top